Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry.
Sign Up to like & getrecommendations! Published in 2021 at "International journal of cardiology"
DOI: 10.1016/j.ijcard.2021.10.138
Abstract: AIM To analyze the prevalence and clinical implications of the eligibility criteria for prolonged dual antithrombotic therapy with ticagrelor 60 mg twice daily and/or rivaroxaban 2.5 mg twice daily in a contemporary real-world ACS registry. METHODS Patients… read more here.
Keywords: dual antithrombotic; eligibility criteria; eligibility; therapy ... See more keywords
Differential prognosis of patients that are candidates for standard, short or prolonged dual antiplatelet treatment discharged after an acute coronary syndrome.
Sign Up to like & getrecommendations! Published in 2022 at "Thrombosis research"
DOI: 10.1093/eurheartj/ehac544.1381
Abstract: BACKGROUND Current evidence supports the efficacy of prolonged dual antiplatelet treatment (DAPT) for patients at high-ischemic risk and low bleeding risk as well as the efficacy and safety of short DAPT in high-bleeding risk (HBR)… read more here.
Keywords: dapt; risk; dapt candidates; dual antiplatelet ... See more keywords
Long-Term Safety and Efficacy of Prolonged Dual Antiplatelet Therapy according to Baseline Anemia after Percutaneous Coronary Intervention
Sign Up to like & getrecommendations! Published in 2022 at "Yonsei Medical Journal"
DOI: 10.3349/ymj.2022.63.3.211
Abstract: Purpose We aimed to evaluate the outcomes of prolonged dual antiplatelet therapy (DAPT) depending on baseline anemia after percutaneous coronary intervention (PCI). Materials and Methods Among the 1470 study participants, 448 (30.5%) were classified as… read more here.
Keywords: anemic patients; baseline anemia; prolonged dual; dapt ... See more keywords